Thema: GB0009895292
AstraZeneca, GB0009895292
AstraZeneca plc (ISIN GB0009895292) prägt mit Impfstoffen und Medikamenten die globale Gesundheitsversorgung und Onkologie-Behandlung - Foto: THN
AstraZeneca stock enters roadshow with 7% revenue growth
AstraZeneca stock heads into a London investor roadshow after strong nine-month results. Pipeline execution remains the key focus for shareholders.
ad-hoc-news.de, heute 09:44 Uhr
AstraZeneca, GB0009895292
AstraZeneca stock faces Nov. 2 roadshow after 7% growth
AstraZeneca meets investors in London on Monday after its latest results kept the 2026 outlook intact. Pipeline execution remains central for shareholders.
ad-hoc-news.de, 01.11.26 17:18 Uhr
AstraZeneca, GB0009895292
AstraZeneca stock: Q3 growth keeps 2026 outlook intact
AstraZeneca stock enters the weekend after strong quarterly growth and fresh US approval for Ultomiris in a rare kidney disease.
ad-hoc-news.de, 31.10.26 10:27 Uhr
AstraZeneca, GB0009895292
AstraZeneca stock: Q3 growth keeps 2026 guidance intact
AstraZeneca stock traded at 167.15 euros on Friday afternoon. Nine-month revenue rose 7% at constant exchange rates as 2026 guidance held.
ad-hoc-news.de, 30.10.26 14:43 Uhr
AstraZeneca, GB0009895292
AstraZeneca stock: Q3 growth supports outlook and pipeline ...
AstraZeneca stock followed a stronger third quarter as oncology and rare diseases offset pressure on Farxiga. Full-year guidance was reaffirmed.
ad-hoc-news.de, 30.10.26 09:24 Uhr
AstraZeneca, GB0009895292
AstraZeneca wins EU Enhertu approval and stock costs EUR ...
EU approval expands Enhertu into early breast cancer treatment. AstraZeneca stock costs EUR 154.10 on October 29, 2026 at Lang & Schwarz.
ad-hoc-news.de, 29.10.26 10:21 Uhr
AstraZeneca, GB0009895292
AstraZeneca presents cancer data as AstraZeneca stock trades ...
Five pivotal Phase III trials headline the ESMO program. AstraZeneca stock costs EUR 152.38 on October 27, 2026 ahead of results on October 30.
ad-hoc-news.de, 27.10.26 09:03 Uhr
AstraZeneca, GB0009895292
AstraZeneca stock: results due October 30 2026 ahead of ...
Barclays maintained its Buy rating on October 26, 2026. At Lang & Schwarz the stock trades pre-market at EUR 153.63 on October 27, 2026.
ad-hoc-news.de, 27.10.26 07:43 Uhr
AstraZeneca, GB0009895292
AstraZeneca reports 42 percent lower death risk: October ...
The VOLGA trial cut recurrence risk 49 percent on October 24, 2026. AstraZeneca stock faces October 30 results after 42 percent lower death risk.
ad-hoc-news.de, 26.10.26 09:00 Uhr
AstraZeneca, GB0009895292
AstraZeneca stock has ESMO event today ahead of the Xetra ...
